IMCC
Price
$2.04
Change
-$0.13 (-5.99%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
1.5M
Intraday BUY SELL Signals
SCYX
Price
$5.16
Change
-$0.21 (-3.91%)
Updated
Oct 2, 04:56 PM (EDT)
Capitalization
45.97M
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMCC vs SCYX

IMCC vs SCYX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMCC vs. SCYX commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMCC is a Hold and SCYX is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
IMCC vs SCYX: Fundamental Ratings
IMCC
SCYX
OUTLOOK RATING
1..100
9745
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
9460
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
49n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMCC's Valuation (24) in the null industry is in the same range as SCYX (26) in the Pharmaceuticals Other industry. This means that IMCC’s stock grew similarly to SCYX’s over the last 12 months.

IMCC's Profit vs Risk Rating (100) in the null industry is in the same range as SCYX (100) in the Pharmaceuticals Other industry. This means that IMCC’s stock grew similarly to SCYX’s over the last 12 months.

SCYX's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as IMCC (100) in the null industry. This means that SCYX’s stock grew similarly to IMCC’s over the last 12 months.

SCYX's Price Growth Rating (60) in the Pharmaceuticals Other industry is somewhat better than the same rating for IMCC (94) in the null industry. This means that SCYX’s stock grew somewhat faster than IMCC’s over the last 12 months.

SCYX's P/E Growth Rating (98) in the Pharmaceuticals Other industry is in the same range as IMCC (100) in the null industry. This means that SCYX’s stock grew similarly to IMCC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMCCSCYX
RSI
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 15 days ago
85%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (IMCC: $2.17 vs. SCYX: $5.37)
Brand notoriety: IMCC and SCYX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: IMCC: 8% vs. SCYX: 299%
Market capitalization -- IMCC: $1.5M vs. SCYX: $45.97M
IMCC [@Pharmaceuticals: Generic] is valued at $1.5M. SCYX’s [@Pharmaceuticals: Generic] market capitalization is $45.97M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMCC’s FA Score shows that 1 FA rating(s) are green while SCYX’s FA Score has 1 green FA rating(s).

  • IMCC’s FA Score: 1 green, 4 red.
  • SCYX’s FA Score: 1 green, 4 red.
According to our system of comparison, SCYX is a better buy in the long-term than IMCC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMCC’s TA Score shows that 4 TA indicator(s) are bullish while SCYX’s TA Score has 5 bullish TA indicator(s).

  • IMCC’s TA Score: 4 bullish, 6 bearish.
  • SCYX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SCYX is a better buy in the short-term than IMCC.

Price Growth

IMCC (@Pharmaceuticals: Generic) experienced а -31.76% price change this week, while SCYX (@Pharmaceuticals: Generic) price change was +20.67% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.71%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +29.84%.

Reported Earning Dates

SCYX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.71% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
IMCC
Daily Signal:
Gain/Loss:
SCYX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SKWD54.781.98
+3.75%
Skyward Specialty Insurance Group
SSTI8.440.13
+1.56%
SoundThinking
SJM115.95-2.96
-2.49%
JM Smucker Company (The)
CIX36.41-0.98
-2.62%
Comp X International
BBLG0.47-0.02
-4.29%
Bone Biologics Corp

IMCC and

Correlation & Price change

A.I.dvisor tells us that IMCC and TXMD have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMCC and TXMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMCC
1D Price
Change %
IMCC100%
-3.56%
TXMD - IMCC
25%
Poorly correlated
-0.49%
ACB - IMCC
24%
Poorly correlated
N/A
CTOR - IMCC
23%
Poorly correlated
-2.97%
SCYX - IMCC
22%
Poorly correlated
+8.70%
SNDL - IMCC
22%
Poorly correlated
-2.33%
More

SCYX and

Correlation & Price change

A.I.dvisor tells us that SCYX and ACET have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
+8.70%
ACET - SCYX
27%
Poorly correlated
-7.00%
ELAN - SCYX
26%
Poorly correlated
-2.77%
CRDL - SCYX
24%
Poorly correlated
-6.02%
IMCC - SCYX
24%
Poorly correlated
-3.56%
TXMD - SCYX
23%
Poorly correlated
-0.49%
More